TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3541724

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 31847602

Group type: EXPERIMENTAL
Intervention: Evening feeding (4 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Morning feeding (4 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comparison of AM vs PM feeding
Number of subjects: 22
Study: 31274244

Group type: EXPERIMENTAL
Intervention: Nonlobar CMB
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Lobar CMB
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: CMB
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Severe confluent WMH
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Age and sex
Number of subjects: 344
Study: 28265762

Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Both Mediterranean diet and physical activity
Number of subjects: 456
Study: 26002536

Group type: EXPERIMENTAL
Intervention: Video-based didactic instruction
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Low-fidelity simulation activities
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High-fidelity simulation activities
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (lecture only)
Number of subjects: 39
Study: 23872824

Group type: EXPERIMENTAL
Intervention: danoprevir/r
Number of subjects: 54

Group type: COMPARATOR
Intervention: placebo/r
Number of subjects: 54
Study: 21572328

Group type: EXPERIMENTAL
Intervention: Procalcitonin arm
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Standard-of-care-only arm
Number of subjects: 1200
Study: 19650947

Group type: EXPERIMENTAL
Intervention: Inhaled pharmacotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guidelines for inhaled pharmacotherapy
Number of subjects: 0
Study: 16615287

Group type: EXPERIMENTAL
Intervention: Colorectal surgery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Orthopaedic surgery
Number of subjects: 20
Study: 14571186

Group type: EXPERIMENTAL
Intervention: Indinavir, zidovudine, and lamivudine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Post-study regimen
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Indinavir, zidovudine, and lamivudine (combined on-study and post-study)
Number of subjects: 33
Study: 10729391

Group type: EXPERIMENTAL
Intervention: Low dose acetylcholine
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High dose acetylcholine
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: CD8-lymphocytes expressing ICAM-1
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Antibodies to oxidized low-density lipoprotein
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Body weight
Number of subjects: 31
Study: 8888218

Group type: EXPERIMENTAL
Intervention: Bolus tracking with 120 mL of contrast material
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fixed scanning delay with 120 mL of contrast material
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bolus tracking with 100 mL of contrast material
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fixed scanning delay with 100 mL of contrast material
Number of subjects: 120
Study: 1490430

Group type: EXPERIMENTAL
Intervention: Desferrioxamine
Number of subjects: 63

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 63
Study: 3859587

Group type: EXPERIMENTAL
Intervention: epirubicin 85 mg/m2
Number of subjects: 54

Group type: COMPARATOR
Intervention: doxorubicin 60 mg/m2
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: epirubicin
Number of subjects: 54

Group type: COMPARATOR
Intervention: doxorubicin
Number of subjects: 54
Study: 28181772

Group type: EXPERIMENTAL
Intervention: Non-invasive method for evaluating pubertal status based on anthropometric variables
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Validation sample (N=52)
Number of subjects: 206
Study: 26467038

Group type: EXPERIMENTAL
Intervention: Continuous wound infiltration (CWI)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Single-injection transversus abdominis plane (TAP) block
Number of subjects: 54
Study: 25182605

Group type: EXPERIMENTAL
Intervention: Heated humidified ventilation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 50
Study: 23066868

Group type: EXPERIMENTAL
Intervention: Ecabet sodium quadruple therapy
Number of subjects: 311

Group type: COMPARATOR
Intervention: Bismuth quadruple therapy
Number of subjects: 311
Study: 20464599

Group type: EXPERIMENTAL
Intervention: Almotriptan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18822996

Group type: EXPERIMENTAL
Intervention: Citalopram at Level 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subsequent treatment options at Levels 2-4 (randomized and open label)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients who did not reach full remission
Number of subjects: 0
Study: 16125588

Group type: EXPERIMENTAL
Intervention: Intravenous artesunate 2.4 mg/kg bodyweight given as a bolus at 0, 12, and 24 h, then daily
Number of subjects: 1461
Study: 11849659

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/d for 6 weeks
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Simvastatin dosage variations (mg/kg/day)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Apo E polymorphism
Number of subjects: 63
Study: 12202047

Group type: EXPERIMENTAL
Intervention: Risedronate (2.5‐ and 5‐mg doses)
Number of subjects: 7981

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7981
Study: 9517503

Group type: EXPERIMENTAL
Intervention: High dose cytarabine and etoposide (HIDAC‐3‐7)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dose combination (7‐3‐7)
Number of subjects: 0
Study: 8038354

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg daily
Number of subjects: 250

Group type: COMPARATOR
Intervention: Ranitidine 300 mg nightly
Number of subjects: 250
Study: 3398651

Group type: EXPERIMENTAL
Intervention: Piroxicam cream (0.5%, 1%, 1.5%)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Indomethacin cream (5%)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Etofenamate gel (1%)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Benzydamine cream (5%)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Piroxicam gel (1%)
Number of subjects: 5
Study: 30995824

Group type: EXPERIMENTAL
Intervention: Inulin Propionate Ester (IPE) incorporated into food products (10 g/d for six days)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (un-supplemented food products)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Inulin Propionate Ester (IPE) incorporated into food products
Number of subjects: 21
Study: 29159176

Group type: EXPERIMENTAL
Intervention: Alternate nostril breathing exercise for 15 minutes
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (quiet room)
Number of subjects: 30
Study: 25555445

Group type: EXPERIMENTAL
Intervention: Art, massage, or music therapy employed in hospices
Number of subjects: 591

Group type: COMPARATOR
Intervention: Larger hospices
Number of subjects: 591

Group type: COMPARATOR
Intervention: For-profit hospices
Number of subjects: 591

Group type: COMPARATOR
Intervention: Hospices in the Mountain/Pacific region
Number of subjects: 591
Study: 23824152

Group type: EXPERIMENTAL
Intervention: 1.0 M gadobutrol
Number of subjects: 51

Group type: COMPARATOR
Intervention: 0.5 M gadoteridol
Number of subjects: 51
Study: 21624490

Group type: EXPERIMENTAL
Intervention: BUD/FM 320/9 μg
Number of subjects: 40

Group type: COMPARATOR
Intervention: FP/SM 250/50 μg
Number of subjects: 40
Study: 18774274

Group type: EXPERIMENTAL
Intervention: PGT plus clonazepam
Number of subjects: 58

Group type: COMPARATOR
Intervention: clonazepam
Number of subjects: 58
Study: 16786913

Group type: EXPERIMENTAL
Intervention: Interscalene (IS) approach
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Interscalene (ISCM) approach
Number of subjects: 81
Study: 12658666

Group type: EXPERIMENTAL
Intervention: Media literacy program
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Self-esteem program
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study: 10934666

Group type: EXPERIMENTAL
Intervention: U.S.-brand warfarin sodium tablet (5 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Generic warfarin product (5 mg)
Number of subjects: 24
Study: 9795574

Group type: EXPERIMENTAL
Intervention: Health education using simple line drawings of reproductive organs and signs of STDs; method not quantified in terms of dosage or duration.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-based health education methods; specifics not quantified.
Number of subjects: 0
Study: 1567574

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX) administered at 20 mg/kg/day plus 100 mg/kg/day for 21 days.
Number of subjects: 163

Group type: COMPARATOR
Intervention: Pentamidine administered at 4 mg/kg/day for 21 days.
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Change in therapy due to failure to respond.
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Change in therapy due to toxicity.
Number of subjects: 163
Study: 29249166

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg b.i.d.
Number of subjects: 12626

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12626
Study: 29031492

Group type: EXPERIMENTAL
Intervention: Assisted Symptom Management (ASM) consisting of automated symptom monitoring by interactive voice recording or Internet and prompted pain and mood self‐management
Number of subjects: 294

Group type: COMPARATOR
Intervention: Comprehensive Symptom Management (CSM) which combines ASM with optimized medication management delivered by a nurse-physician specialist team and facilitated mental health care
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Assisted Symptom Management (ASM)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Comprehensive Symptom Management (CSM)
Number of subjects: 294
Study: 27451854

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (NADA protocol)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (local protocol)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Relaxation (control)
Number of subjects: 280
Study: 23926046

Group type: EXPERIMENTAL
Intervention: Frustration induction
Number of subjects: 330

Group type: COMPARATOR
Intervention: No frustration induction
Number of subjects: 330
Study: 21965517

Group type: EXPERIMENTAL
Intervention: 6-month exercise-based cardiac rehabilitation (group T)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Generic instructions for maintaining physical activity (group C)
Number of subjects: 50
Study: 20493487

Group type: EXPERIMENTAL
Intervention: FICE (Fuji Intelligent Color Enhancement)
Number of subjects: 359

Group type: COMPARATOR
Intervention: WL (Conventional White-Light Colonoscopy)
Number of subjects: 359
Study: 17608233

Group type: EXPERIMENTAL
Intervention: Yishen Yangnao capsule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dukexi slice (control)
Number of subjects: 0
Study: 16125497

Group type: EXPERIMENTAL
Intervention: Beta blockers (higher doses in the upper quartile)
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Beta blockers (both dosage levels)
Number of subjects: 691

Group type: COMPARATOR
Intervention: Beta blockers (lower doses in the lower 3 quartiles)
Number of subjects: 691
Study: 12244291

Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.50% (1 mg/kg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: racemic bupivacaine 0.50% (1 mg/kg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.75% (1.4 mg/kg)
Number of subjects: 45
Study: 10334137

Group type: EXPERIMENTAL
Intervention: Adult-onset asthma while employed
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Recrudescence of previously quiescent childhood-onset asthma during employment
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Occupations at increased risk of occupational asthma initiation
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Occupations at increased risk of exposures aggravating asthma
Number of subjects: 150
Study: 7789139

Group type: EXPERIMENTAL
Intervention: Experimental arms (specific intervention details not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (specific details not provided)
Number of subjects: 0
Study: 1962904

Group type: EXPERIMENTAL
Intervention: Fragmin (FR‐860)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional heparin
Number of subjects: 61
Study: 7272152

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atropine and Metoclopramide (combined administration)
Number of subjects: 12
Study: 31589541

Group type: EXPERIMENTAL
Intervention: TD group
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: SSD-contrast group
Number of subjects: 3

Group type: COMPARATOR
Intervention: SSD-collapse group
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Covert contrast
Number of subjects: 3
Study: 28822660

Group type: EXPERIMENTAL
Intervention: Guidewire exchange (GE)
Number of subjects: 678

Group type: COMPARATOR
Intervention: Catheter removal (CR)
Number of subjects: 678
Study: 26740065

Group type: EXPERIMENTAL
Intervention: Fugl-Meyer Assessment of the lower extremity (FMA-LE)
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Rasch analysis rating scale model
Number of subjects: 535
Study: 25078374

Group type: EXPERIMENTAL
Intervention: Pre-germinated brown rice (PGBR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: White rice (WR)
Number of subjects: 60
Study: 21751879

Group type: EXPERIMENTAL
Intervention: Topical N-acetyl-cysteine (NAC) 5%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Topical steroid-antibiotic combination (betamethasone 0.1%-sulfacetamide sodium 10%)
Number of subjects: 20
Study: 19733608

Group type: EXPERIMENTAL
Intervention: Divergent thinking training program
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control program on convergent thinking
Number of subjects: 17
Study: 17513628

Group type: EXPERIMENTAL
Intervention: Repeat dose of ondansetron 4 mg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Granisetron 0.1 mg
Number of subjects: 88
Study: 15118190

Group type: EXPERIMENTAL
Intervention: 6.4% carbohydrate‐electrolyte (CHO) solution
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PLA) solution
Number of subjects: 8
Study: 11451122

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated tapered pins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard tapered pins
Number of subjects: 0
Study: 9526460

Group type: EXPERIMENTAL
Intervention: Augmented student feedback (norm-referenced, graphic summaries and individualized teaching-effectiveness guidelines)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no augmented feedback)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Residents with medium or high baseline scores
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Residents with low baseline scores
Number of subjects: 81
Study: 7805634

Group type: EXPERIMENTAL
Intervention: AIDS-prevention group
Number of subjects: 206

Group type: COMPARATOR
Intervention: Health-promotion group
Number of subjects: 206

Group type: COMPARATOR
Intervention: No-intervention group
Number of subjects: 206
Study: 3182111

Group type: EXPERIMENTAL
Intervention: May and Baker preparation of metronidazole (200 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Servipharm preparation of metronidazole (200 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: May and Baker preparation of metronidazole
Number of subjects: 8

Group type: COMPARATOR
Intervention: Servipharm preparation of metronidazole
Number of subjects: 8
Study: 30374191

Group type: EXPERIMENTAL
Intervention: Buprenorphine/samidorphan (BUP/SAM) 2 mg/2 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30958334

Group type: EXPERIMENTAL
Intervention: Virtual Reality exercise program (Nintendo Wii Fit Plus), 10 minutes of strength and 10 minutes of balance exercises
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional exercise program (TheraBand), 10 minutes of ankle strength exercises and 10 minutes of balance exercises
Number of subjects: 21
Study: 28284167

Group type: EXPERIMENTAL
Intervention: Albiglutide
Number of subjects: 0
Study: 26041677

Group type: EXPERIMENTAL
Intervention: High-phytate (HP) diet
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low-phytate (LP) diet
Number of subjects: 32
Study: 23704060

Group type: EXPERIMENTAL
Intervention: Dobutamine stress MR imaging (DS‐MR) at 10 μg/kg/min and 20 μg/kg/min
Number of subjects: 18

Group type: COMPARATOR
Intervention: Dobutamine stress MR imaging (DS‐MR) in normal volunteers
Number of subjects: 18
Study: 22833195

Group type: EXPERIMENTAL
Intervention: rs7600563 (genetic variant)
Number of subjects: 7860
Study: 19005170

Group type: COMPARATOR
Intervention: SIENA
Number of subjects: 43

Group type: COMPARATOR
Intervention: CCV
Number of subjects: 43

Group type: COMPARATOR
Intervention: SIENAX
Number of subjects: 43
Study: 17990453

Group type: EXPERIMENTAL
Intervention: Combined treatment with compound Reinhartdt and Sea Cumber Capsule (RSC) and Donepezil
Number of subjects: 63

Group type: COMPARATOR
Intervention: Donepezil
Number of subjects: 63

Group type: COMPARATOR
Intervention: RSC
Number of subjects: 63
Study: 16359481

Group type: EXPERIMENTAL
Intervention: Polymethylvinylether‐maleic anhydride (PVM‐MA) adhesive paste
Number of subjects: 30

Group type: COMPARATOR
Intervention: Carboxymethyl cellulose (CC) adhesive paste
Number of subjects: 30

Group type: COMPARATOR
Intervention: Retention of maxillary dentures
Number of subjects: 30

Group type: COMPARATOR
Intervention: Taste
Number of subjects: 30

Group type: COMPARATOR
Intervention: Removal of the adhesive
Number of subjects: 30
Study: 11756370

Group type: EXPERIMENTAL
Intervention: Discrete time Markov chain analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard analyses
Number of subjects: 0
Study: 9820719

Group type: EXPERIMENTAL
Intervention: Low flow-rate (LFR) group with 2.5 L/min insufflation
Number of subjects: 76

Group type: COMPARATOR
Intervention: High flow-rate (HFR) group with 7.5 L/min insufflation
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Operation time for LFR
Number of subjects: 76

Group type: COMPARATOR
Intervention: Operation time for HFR
Number of subjects: 76
Study: 7641736

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide with RDI > median value
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cyclophosphamide with RDI < median value
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cisplatin with RDI > median value
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cisplatin with RDI < median value
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: CP regimen with ARDI > median value
Number of subjects: 43

Group type: COMPARATOR
Intervention: CP regimen with ARDI < median value
Number of subjects: 43
Study: 2655685

Group type: EXPERIMENTAL
Intervention: zofenopril
Number of subjects: 38

Group type: COMPARATOR
Intervention: hydrochlorothiazide
Number of subjects: 38
Study: 336057

Group type: EXPERIMENTAL
Intervention: Rheumon Gel (etofenamate)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo Gel
Number of subjects: 69
Study: 30375187

Group type: EXPERIMENTAL
Intervention: O-R electric toothbrush with novel round brush head (EB60) on an Oral-B Vitality O-R handle (D12)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Manual toothbrush (ADA manual toothbrush)
Number of subjects: 150
Study: 28193616

Group type: EXPERIMENTAL
Intervention: Topical application of betamethasone valerate 0.1% cream twice a day for 6 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 25297572

Group type: EXPERIMENTAL
Intervention: Glibenclamide (2.5 mg) tablets twice daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 23582525

Group type: EXPERIMENTAL
Intervention: Theory-based HIV educational video (102 participants)
Number of subjects: 203

Group type: COMPARATOR
Intervention: In-person HIV counseling session (101 participants)
Number of subjects: 203
Study: 21481651

Group type: EXPERIMENTAL
Intervention: Peak 1 NFR (single ascending series of stimulations)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Staircase NFR (3 ascending/descending staircases of stimulations)
Number of subjects: 0
Study: 19092650

Group type: EXPERIMENTAL
Intervention: Every other day hemodialysis (eodHD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional hemodialysis (cHD)
Number of subjects: 18
Study: 17053552

Group type: EXPERIMENTAL
Intervention: Spironolactone 25-50 mg once daily
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 15525445

Group type: EXPERIMENTAL
Intervention: Desmopressin (0.2 microg) administered intravenously
Number of subjects: 16

Group type: COMPARATOR
Intervention: Piroxicam administered to achieve steady state
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Desmopressin (2 microg) administered intravenously
Number of subjects: 16
Study: 10443770

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 600 microg/kg/hr
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7529467

Group type: EXPERIMENTAL
Intervention: Aprotinin (3.8 x 10(6) Kallikrein inactivation units)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 53
Study: 2192099

Group type: EXPERIMENTAL
Intervention: Abana (800 mg tds)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Methyldopa (M-DOPA, 250 mg tds)
Number of subjects: 43
Study: 457528

Group type: EXPERIMENTAL
Intervention: Aspirin and dipyridamole premedication after 3 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo medication after 3 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups at high altitude
Number of subjects: 16
Study: 31781694

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) gel applied topically on the day of frenectomy and on days 3, 7, and 14 postoperatively
Number of subjects: 40

Group type: COMPARATOR
Intervention: No application of HA gel (Control)
Number of subjects: 40